DDX49 and metastatic malignant neoplasm in the lymph nodes: In this study, we observed that DDX49 was highly expressed in CRC tissues, with its expression level significantly correlating with adverse clinicopathological features (including tumor stage and lymph node metastasis) and worse patient survival.